Logo

People in the News: James LaFrance, Thomas McLain

Apr 25, 2014
Premium

Vermillion has appointed James LaFrance, chairman of the firms' board of directors, to succeed Thomas McLain as president and CEO.

LaFrance, who will continue to serve as Vermillion's board chairman, formerly was CEO of Omnyx. He also held executive leadership posts at Ventana Medical Systems and Bayer Diagnostics.

Filed under

Proteomics & Protein Research
proteomics
Vermillion
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.